Pharmatec/Medco Research/University of Florida joint venture will develop and market therapeutic and diagnostic products consisting of a combination of adenosine and its derivatives in the patented Pharmatec carrier system. Joint venture company will conduct research into the Adenosine Carrier's ability to enhance the penetration of adenosine into the brain with the expectation of producing anti-convulsant, anti-anxiety, anti-depressant and hypnotic activity.
You may also be interested in...
In a recent PR campaign for Calpol in the UK, Johnson & Johnson Consumer Health partnered with children’s charity NSPCC to raise awareness of the latter's helpline. HBW Insight speaks exclusively to J&J's head of Marketing for Northern Europe at J&J Consumer Health, Hannah French.
Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the oncology drug while the originator's patent stands valid.